BioSpace News Archive

Junshi Biosciences announced that the United States Food and Drug Administration has expanded the emergency use authorization for etesevimab and bamlanivimab administered together to include certain high-risk pediatric patients from birth to under 12 years old for the treatment of mild to moderate COVID-19 as well as post-exposure prophylaxis, according to Eli Lilly and Company, the company’s global partner.

Brii Biosciences Limited, announced that the Company has been added to the Hong Kong Stock Connect.

Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways.

Juvenile macular dystrophy, also known as juvenile macular degeneration, refers collectively to a group of rare and genetic inherited eye disorders that can affect children and young adults.

Increasing importance of education in the healthcare industry to address organizational challenges and deliver improved care has led to the merger of healthcare, technology and digital solution providers to develop healthcare education solutions.

Centesis catheter has a tapered tip and smooth transitions used to decrease resistance for less patient discomfort. Its various types of needle allow for more accurate placement.

Fact.MR – A Market Research and Competitive Intelligence Provider: Sales of animal parasiticides are forecast to grow at a steady 5.9% between 2020 and 2026, as per a market survey by Fact.MR.

Rising number of surgical procedure in the hospitals and clinics likely to influence demand for the global market for hospital gowns market in coming years.

Catheter-related bloodstream infections occur due to presence of bacteremia. It is one of the most frequent, lethal, and costly complications of central venous catheterization and the most common cause of nosocomial bacteremia.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global anti-snoring devices and snoring surgery market is expected to expand at a 7.2% CAGR, reaching US$ 40 Bn by 2031.